The estimated Net Worth of David Apelian is at least $2.6 Million dollars as of 16 August 2022. David Apelian owns over 5,000 units of Eiger BioPharmaceuticals Inc stock worth over $18,975 and over the last 11 years he sold EIGR stock worth over $49,050. In addition, he makes $2,534,300 as Director at Eiger BioPharmaceuticals Inc.
Sign up
David Apelian EIGR stock SEC Form 4 insiders trading
David has made over 3 trades of the Eiger BioPharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of EIGR stock worth $49,050 on 16 August 2022.
The largest trade he's ever made was exercising 10,000 units of Eiger BioPharmaceuticals Inc stock on 30 December 2015 worth over $30,200. On average, David trades about 1,471 units every 142 days since 2013. As of 16 August 2022 he still owns at least 11,000 units of Eiger BioPharmaceuticals Inc stock.
You can see the complete history of David Apelian stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Apelian biography
Dr. David Apelian M.D. Ph.D. serves as Director of the Company. He is no longer Chief Operating Officer and Executive Medical Officer of the Company, effective June 14, 2019. Dr. Apelian was most recently Executive VP and Chief Medical Officer of Achillion Pharmaceuticals, Inc., a position he held since 2013. At Achillion, he was responsible for creating portfolio strategy and managing the company's clinical development programs. He was instrumental in securing a partnership between Achillion and J&J, which resulted in a$225 millionequity investment. More recently, he led the rare disease development program for novel small-molecule complement factor D inhibitors for alternative pathway-mediated diseases. From 2005 to 2013, Dr. Apelian was Chief Medical Officer and subsequently head of all R&D and Regulatory Affairs for GlobeImmune. He was previously at Bristol-Myers Squibb where he served as Clinical Director and Medical Leader for development of Baraclude ® (entecavir) for chronic HBV through NDA filing. Prior to that, Dr. Apelian was Clinical Director in the Department of Hepatology & Gastroenterology at Schering Plough, where he coordinated a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic HCV. Dr. Apelian completed his residency training in pediatrics at New York Hospital, Cornell Medical Center and is board certified in Pediatrics. He received a PhD in Biochemistry from Rutgers University, an MD from the University of Medicine and Dentistry of New Jerseyand an MBA from Quinnipiac University. He earned a BA in Biochemistry from Rutgers University.
What is the salary of David Apelian?
As the Director of Eiger BioPharmaceuticals Inc, the total compensation of David Apelian at Eiger BioPharmaceuticals Inc is $2,534,300. There are 1 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.
How old is David Apelian?
David Apelian is 55, he's been the Director of Eiger BioPharmaceuticals Inc since 2019. There are 12 older and 6 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.
What's David Apelian's mailing address?
David's mailing address filed with the SEC is C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO, CA, 94306.
Insiders trading at Eiger BioPharmaceuticals Inc
Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman, and Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.
What does Eiger BioPharmaceuticals Inc do?
eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.
What does Eiger BioPharmaceuticals Inc's logo look like?
Complete history of David Apelian stock trades at Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals Inc executives and stock owners
Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Cory,
President, Chief Executive Officer, Director -
David Apelian,
Director -
Stephana Patton,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Sriram Ryali,
Chief Financial Officer -
David A. Cory M.B.A., R.Ph., R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
James Shaffer,
Chief Business Officer -
David A. Cory R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
Eldon C. Mayer III, M.B.A.,
Exec. VP & Chief Commercial Officer -
Sriram Ryali M.B.A.,
Chief Financial Officer -
Christine Murray,
Independent Director -
Thomas Dietz,
Independent Chairman of the Board -
Amit Sachdev,
Independent Director -
Evan Loh,
Independent Director -
Eldon Mayer,
Executive Vice President, Chief Commercial Officer -
Jeffrey Glenn,
Independent Director -
Dr. Evan Loh,
CEO of Paratek Pharmaceuticals & Director -
Dr. Jeffrey S. Glenn,
Founder, Scientific Advisor & Independent Director -
Dr. Stephana E. Patton J.D., Ph.D.,
Consultant -
Erik Atkisson,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Dr. Colin Hislop,
Sr. VP of Clinical & Devel. Operations -
Rich Franco M.B.A.,
Sr. VP & Progeria Program Lead -
Dr. Ingrid C. Choong,
Sr. VP of Clinical Devel. -
Charles Bramlage,
Director -
Edgar Engleman,
Director -
Joanne Quan,
Chief Medical Officer -
Eduardo Bruno Martins,
SVP, Liver and Infectious Dise -
Ventures Vi, Llc Vivo Ventu...,
-
James H Welch,
Chief Financial Officer -
Nina S Kjellson,
Director -
Kim Sablich,
-
Partners X Lp Inter West Ma...,
-
Ingrid Choong,
Chief Business Officer -
Erik Atkisson,
GC & Chief Compliance Officer -
Lisa Kelly Croswell,
-
James Vollins,
General Counsel -
Leen Kawas,
-
Richard A Kayne,